Abstract
Objective To examine whether optoretinography (ORG) can provide greater sensitivity for assessing the time-course of disease progression in Retinitis Pigmentosa compared to standard clinical imaging in a longitudinal study,
Design Cohort, longitudinal study.
Participants Five non-syndromic RP patients and eight control subjects participated in the study.
Methods Clinical examination, imaging sessions and data analysis were all conducted at the University of Washington. Five eyes of 5 patients diagnosed with RP, comparing standard clinical imaging to ORG, were collected over a 21-month span between August 2022 and May 2024.
Main outcome and measures ORG response to visual stimuli, ellipsoid zone (EZ) width and outer segment length (OS length) were evaluated for longitudinal changes as markers of disease progression.
Results The reduction in cone function with ORG over time exceeds that observed in standard clinical markers of photoreceptor structure - EZ width and OS length. EZ width and OSL decreased by 4.5% ± 5.9% and 6.5% ± 1.4%, respectively, approximately 9.9 and 6.9 times less than the reduction noted in ORG, respectively. The most notable degradation was noted at the borders of the transition zone, where ORG showed progressive and sub-clinical losses in photoreceptor function whereas standard OCT showed healthy, unaffected outer retinal structure.
Conclusions Optoretinography detects sub-clinical disease and reliably identifies longitudinal markers of progression with greater sensitivity compared to standard clinical imaging. The ability to detect functional changes in the outer retina prior to standard clinical measures underscores its potential as a sensitive, accelerated and clinically-relevant outcome measure to guide patient selection and their therapeutic response in future clinical trials.
Introduction
Sensitive biomarkers of retinal health are critical for monitoring disease progression and evaluating therapeutic response 1,2. Current clinical imaging tools are limited in their sensitivity and resolution to detect subtle degradation in retinal structure and function. This precludes early diagnosis and treatment, limiting visual recovery as there is a critical window for therapeutic intervention 3. Optical coherence tomography (OCT) and fundus autofluorescence (FAF) are hallmark structural measures of the outer retinal complex. Primary biomarkers include the ellipsoid band width on OCT 4–8 and hyper-autofluorescent (hyper-AF) rings on FAF 9–12. It remains unclear to what extent the remnant structure of photoreceptors still supports normal function. Furthermore, studies have shown that in advanced stages of disease, OCT and FAF reveal only minor changes over time, making it difficult to detect incremental progression or an accurate response to treatment 13,14. Clinical functional assessments, including BCVA 15,16, perimetry 17 and electroretinogram (ERG) 18,19, offer complementary information about retinal integrity. BCVA and perimetry represent the cumulative output of the entire visual system and are thus limited in their cellular specificity. Moreover, mechanisms in the retina and cortex that compensate for photoreceptor loss can allow patients to largely ignore visual symptoms until late in the disease process 15,20,21. The gold standard objective measure of retinal functional activity is ERG, but it lacks the spatial resolution to detect localized changes, particularly in advanced stages of disease 22. The urgent need for a non-invasive and sensitive biomarker of retinal disease progression has taken on renewed importance in the light of recent gene therapy clinical trials that have shown promise to restore outer retinal function 23–28.
Optoretinography (ORG) marks a significant advance in the non-invasive and sensitive monitoring of retinal structure and function in vivo. When implemented in an OCT, it provides a direct optical measure of light-evoked photoreceptor activity 29–37 in conjunction with the underlying three-dimensional structure responsible for the functional assay. The activity is linked to the initial steps in vision that originate in the outer retina - light absorption, photoisomerization, phototransduction and the visual cycle 34,38. A few recent studies have demonstrated the ability of ORG to detect sub- clinical changes in RP 21,39,40, particularly in the transition zone at the border of healthy and diseased areas, highlighting its potential for accurate disease assessment.
RP is the most common inherited retinal degeneration (IRD) and is the target of various therapeutic approaches 23,41,42. Whereas no approved treatments are available to halt or reverse the progression of RP, several clinical trials are underway 43–45. Clinical and high-resolution adaptive optics (AO) imaging have revealed the common outer retinal phenotypes in RP - reduction in EZ width 6–8,11,46,47, OS length 48–50 and cone density 6,8. Visual acuity 51 and perimetry 17 reveal progressive visual field constriction that eventually affects the central fovea. ERG 19,52–54 typically shows reduced or absent a- and b-waves, reflecting photoreceptor degeneration and inner retinal remodeling. Overall, these metrics show between 4-13 % annual rates of RP progression 6,19,55.
Here, in the first application of ORG to a longitudinal study, we test the hypothesis that cone dysfunction measured with ORG precedes the deterioration exhibited by standard clinical biomarkers in RP patients. We hypothesize that the ORG can detect photoreceptors in their earliest stages of outer segment compromise, at the border between the healthy-appearing central island and transition zone, where structural imaging suggests normal status. This retrospective longitudinal study spanned 12 to 21 months in 5 RP patients and compared ORG findings with EZ width and OS length in quantifying progression.
Method
Study participants
Five patients (ages 23–60 years-old (yo), mean: 33.4 yo) diagnosed with RP based on clinical presentation and relevant family history at the Karalis Johnson Retina Center, Department of Ophthalmology at University of Washington were enrolled in the study. All participants underwent genetic testing through CLIA-approved labs and four (RP02 – RP05) had a confirmed molecular genetic diagnosis (Table 1). Although genetic testing for RP01 was inconclusive, their clinical exam, imaging, Goldmann Visual Fields, and electrophysiology testing were consistent with RP. Research procedures followed the tenets of the Declaration of Helsinki. Eight age-matched normal controls were also enrolled in the study. Informed consent was obtained from all patients, and research protocols were approved by the institutional review board of the University of Washington (IRB#STUDY00002923). Patient characteristics are listed in Table 1.
Research imaging procedures were performed over three visits: baseline, first follow-up (f/u #1), and second follow-up (f/u #2), with a minimum of six months between each follow-up visit. The maximum length of follow-up ranged from 12 to 21 months. Cycloplegia was induced by 1% tropicamide ophthalmic solution for imaging.
The study involved standard clinical testing including OCT (Spectralis HRA+OCT system; Heidelberg Engineering, Vista, CA, USA), color fundus photography and fundus autofluorescence (FAF) (Optos, Marlborough, MA, USA). These conventional measures were compared to ORG (Figure 1).
Overview of study design, illustrating the advanced structure-function assessment. OCT volumes along with the segmented en face image at the inner/outer segment-ellipsoid zone (ISOS-EZ) and outer segment tips (COST) help visualize the retinal structure (A). A zoomed-in view of OCT B-scans provides the outer retinal profile (red line) from which the OS length is obtained and plotted as a function of eccentricity in a color map (B). Warmer and cooler colors represent longer and shorter OS lengths respectively. Retinal function is assessed by measuring the change in outer segment optical path length (ΔOPL) evoked by a light stimulus (shaded green) – denoted as the ORG amplitude (D). The saturated ORG amplitude is obtained from the time evolution of the functional response, shown in (D) for a near-foveal (gray) and parafoveal (black) retinal location. The shaded areas around the solid lines indicate the standard-deviation of repeat measurements. The variation of the saturated ORG is plotted as a function of eccentricity in a color map (E). Test-retest (left) and Bland-Altman analysis (right) shows high repeatability for both OS length (C) and ORG (F).
ORG: imaging system, protocol and analysis
ORG was acquired using a custom-built, line-scan spectral domain OCT system with 3° × 5.5° field-of-view, whose details are described previously 56. First, after a 1-minute dark adaptation, fifty OCT volumes were recorded at 32 Hz. Single OCT volumes were reconstructed and registered with each other to compensate for small eye movements, rendering an averaged, high signal-to-noise ratio OCT volume (Fig 1A) for further analysis. Next, segmentation of the outer retinal layers – the inner-outer segment (ISOS)-ellipsoid band and the outer segment tips, yielded en face 2D images of these layers (Fig 1A) as well as the length of the cone outer segment (Fig 1B). Although EZ width is a well-recognized clinical biomarker of RP, it reflects the preserved portion of the photoreceptor inner segment and therefore does not provide information on outer segment integrity. Sub-clinical changes, such as shortening of the outer segment, can still occur within the EZ area in RP. Therefore, in addition to EZ width (Table 1) derived from clinical OCT based on the presence of the ISOS-ellipsoid band (as determined by three independent graders), this study also used the OS length as a structural measure of disease status. Fig 1B shows the characteristic decline in OS length radiating outward from the foveal center. Note that the measures of cone structure and function, OS length, EZ width and ORG, were all obtained from the same retinal location for each follow-up visit, facilitating spatially localized comparison between them.
The cone ORG, i.e. light-evoked activity in cone OS, was measured following a green stimulus (532 ± 5 nm) of photon density 14.1×106 photons/µm2, chosen to provide a similar and high activation of L and M-cones. The cone ORG response is defined as the change in the cone OS length evoked by a light stimulus as a function of time, as illustrated in Fig. 1C. It is computed as the change in optical phase (converted to optical path length (ΔOPL)) between the ISOS-EZ and cone outer segment tips (COST). In the typical single-flash stimulus paradigm shown here, the ΔOPL exhibits a rapid, low amplitude reduction immediately after stimulus onset, followed by a sharp increase and a saturated plateau (Fig. 1C). Saturated ORG response is calculated as the average ΔOPL over ∼300 ms during the plateau, as shown in Fig. 1D. In a typical healthy control, the saturated ORG scales linearly with OS length (and eccentricity), whereby longer foveal OS exhibits larger ORG responses and shorter peripheral cones have proportionally reduced ORG56, as shown in Fig. 1B&D. The entire ORG procedure was completed in 25 ± 10 mins.
Test-retest variability and statistical analysis
Figures 1C&F illustrate scatter plots of test-retest variability (left) for OS length and ORG in normal controls, showing minimal changes over two visits, spaced 6-months apart. Each scatter plot includes a linear fit line, which closely approximates the identity line (y = x), indicating strong agreement between measurements from the two visits. Figures 1C&F display Bland-Altman plots (right) for OS length and ORG. In these plots, the mean difference (bias) between visits is close to zero for both parameters, indicating no significant systematic bias. Most data points fall within the limits of agreement (±1.96 SD), suggesting minor measurement variability for both OS length and ORG. To further assess the reliability and repeatability, test-retest variability was analyzed by calculating the coefficient of variation (CV) (CV = (SD/Mean) ×100%) for EZ width, OS length, and ORG across repeat measurements. Additionally, Wilcoxon signed-rank tests were used to examine intra-subject variability in reductions of these metrics, providing a means to analyze paired differences for non-normally distributed data. The CVs of 1.5% for EZ width, 3.0% for OS length, and 4.0% for ORG, confirm comparable measurement reliability across these metrics.
Results
Table 1 lists age, sex, genetic diagnosis, clinical presentations, follow-up duration, and changes in BCVA and EZ width of the RP participants included in the study. Over the course of follow up, there was minimal change in BCVA (Table 1). The EZ width captured on a commercial OCT macular B-scan revealed variable progression across the cohort. Study participants experienced a reduction in EZ width ranging from 0.9% to 15% (mean: 4.5% ± 5.9%) over varying follow-up periods of 12 to 21 months.
The most significant EZ width progression of 15% over 20 months of follow-up was seen in Subject RP01. We detail the complete procedure, including both the clinical and advanced imaging with this subject as an example (Fig. 2). Clinical OCT B-scans and FAF images in Fig. 2 (A-B) illustrate visible changes between baseline and follow-up visits. Within the EZ area, where subtle and early changes might not be distinguishable using clinical biomarkers alone, ORG imaging was applied to an area aligned with the FAF (blue rectangle, white ellipse, Fig 2B & 2C). At baseline, near the border of the healthy island and transition zone (yellow ellipse), a complete loss of OS tip reflection precludes reliable OS length and ORG measurements. The OS length map shows a radial decrease from the fovea to the periphery both at baseline and follow-up.
Example longitudinal study analysis pipeline for RP01. (A) Clinical OCT B-scans from baseline (top) and follow-up (bottom) visit. Red arrows indicate the fovea. Red & yellow dashed lines mark the EZ width boundaries at baseline and follow-up respectively. (B) Fundus autofluorescence (FAF) from baseline (top) and follow-up (bottom) visit. The white dashed ellipse outlines the EZ area, while the blue rectangle marks the region selected for further OCT-ORG analysis. (C) En face images for baseline (top) and follow-up (bottom), with the corresponding EZ area from (B) marked as a white dashed ellipse. The yellow ellipse highlights the area chosen for OSL and ORG analysis, based on the preservation of all outer retinal layers. Maps of (D) OS length and (E) ORG amplitude are shown for baseline (top) and follow-up (bottom). An outline is drawn in the OS length and ORG maps, as reference for comparison between baseline and follow-up visits.
However, at follow-up, a reduction in OS length is noted at locations close to the edge of the healthy zone, that is greater in magnitude for the temporal retina. The ORG map follow-up reflects the patient’s general trend of overall reduction in OS length, with the temporal meridian showing the greater progression. In both OS length and ORG, the progression is expectedly most evident at the frontier of degeneration at the border of the healthy island and transition zone. Together, figures 2D-E demonstrate that, even in healthy regions appearing intact on FAF and OCT, advanced ORG imaging not only reveals progressive changes in retinal structure, but also reduced function over time.
Figures 3A-3C display en face OCT images segmented at the ISOS-EZ, OS length maps, and ORG amplitude maps for RP03, RP04 and RP05. The red boxes indicate ROIs selected for ORG. The gradual reduction in OS length and ORG versus eccentricity is evident both at baseline and follow-up for all cases, similar to normal controls (Fig 1). In RP03, both OS length and ORG show a significant reduction along the border of the healthy island and transition zone (Fig. 3B, yellow dashed line). The difference in structural and functional readouts are apparent, where the OS length shows a gradual reduction at the edge of the healthy zone, while the ORG shows more drastic decline.
Longitudinal follow-up in RP03, RP04, and RP05, displaying the progression from the initial baseline visit to the most recent follow-up. (A) Baseline and follow-up en face images at the ISOS-EZ band and the corresponding ROIs (red) selected for OS length and ORG analysis. Maps of OS length and ORG are shown in (B) and (C) respectively. Their corresponding color bars denote the variation in OS length and ORG response amplitude. Yellow dashed lines and arrows indicate the same location for reference across follow-ups.
In RP04, OS length changes are minor and nearly indistinguishable upon visual inspection of the color maps. Yet ORG reductions are observed, where only minor changes are observed in cone structure as assessed by OS length (yellow arrows, Fig. 3). In the early-stage patient RP05, as defined by minimal symptoms and greater preservation of clinical metrics, both OS length and ORG remained stable over time and no changes were apparent upon visual inspection. Of note, RP03 (age range: 56 - 60 yo) and RP05 (age range: 26 - 30 yo) are both affected by variants in the RHO gene (RP03: c.165C>A, p.Asn55Lys; RP05: c.68C>A, p.Pro23His in RP05), but exhibit distinct progression patterns presumably due to their distinct genotypes and disease stage.
The ORG maps reveal a drop in amplitude at the borders of the healthy zone over time, whereas OS length shows comparably lower reductions in the same areas. On the other hand, OS length and ORG remain more stable near the fovea, indicating structural and functional preservation in locations away from the active area of degeneration, i.e. the transition zone. Although the disease progression is minimal near the fovea, the absolute ORG magnitude is indeed decreased in RP compared to normal controls (see Table 2). Previously, the reduction of ORG in the parafovea was shown to correspond with normal microperimetry in RP 21. These qualitative observations highlight nuanced structural and functional changes detectable by ORG, even in regions previously considered stable via standard clinical assessment. Next, we performed a quantitative comparison between ORG, OS length and EZ-width as an objective basis for evaluating progression in RP.
To derive relevant metrics for disease and potential clinical trials, we divided the ORG into three spatial sections for further assessment: ORGtot denoting the overall ORG amplitude across the measurable region, where the measurable region is defined by the presence of both the ISOS-ellipsoid and COST bands; ORGedge denoting the ORG response in the border region surrounding the healthy island; and ORGcent denoting the ORG response in the central healthy region. This is analogous to the “hill of vision” metric 57,58 for documenting the rate of progression in established natural history studies such as the USH2A-related retinal degeneration or RUSH2A study. ORGedge and ORGcent were calculated based on the mean ORG of 10 regions of interest, each of size 0.25° × 0.25°, near the border of the healthy island and in the central fovea respectively (marked by white dots in Fig 4A). The ORGtot was calculated as the mean ORG response for the whole measurable area (white dashed line in Fig. 4A). The comparison between these spatially distinct metrics is shown in Fig. 4B. ORGedge is the most sensitive for assessing progression and demonstrates the largest reduction over time, highlighting the active degradation at the boundary of the transition zone. The corresponding changes in OS length for the same spatial sub-divisions - indicated as OSLtot, OSLedge, and OSLcent - are illustrated in Fig. 4C. The greater reduction in OSLedge compared to OSLtot and OSLcent is evident in RP01, 03 and 04, while this difference is not apparent for the other two cases.
Comparison of biomarkers for detecting RP disease progression. (A) The ORG maps are divided into regions-of-interest (ROIs) (white circles) to allow regional comparison of photoreceptor dysfunction. ORGedge and ORGcent are derived from ROIs at the border of the healthy island and in the central fovea, respectively, while ORGtot is obtained from the entire ORG map. The fovea is indicated by a red star. (B) Comparison of regional metrics derived from ORG, including ORGtot, ORGedge, and ORGcent. (C) Corresponding metrics from OS length, including OSLtot, OSLedge, and OSLcent in (C). (D) Scatter and bar plots showing the percentage reduction in ORGedge amplitude over time for the five RP patients, with pink and purple shades representing the first and second follow-up visits, respectively. Connecting lines illustrate ORG changes for the same imaged location across the different follow-ups. Statistical significance values obtained from the Wilcoxon signed-rank test are noted for (D).
With the knowledge that ORGedge was the most sensitive in detecting longitudinal changes, we plotted the change of this metric for the two follow-ups (Figure 4D). It was evident that by 9 months after their baseline visit, there was detectable disease progression in RP03 and RP04, as indicated by the reduction in ORGedge at the first follow-up – 65.1% and 13.5% respectively. For RP01 and RP02, the first follow up of 16 and 14 months respectively showed an ORGedge reduction of 34.9% and 40.7% respectively. There was a notable decrease in ORGedge amplitude for all patients at both follow-ups, apart from RP05: f/u #1: mean = 31.5% ± 6.7% (range: 3.6% - 65.1%) and f/u #2: mean = 44.7% ± 5.3% (range: 4.3% - 76.7%). For RP01 – 03, the progression was statistically significant for both follow-ups compared to baseline (p <0.005). For RP04, the progression from baseline to 1st follow-up was not statistically significant (p = 0.084), while the progression from baseline to the 2nd follow-up was significant (p = 0.02). In these four cases, cone function deteriorated significantly in the time-interval between the two follow-up visits, demonstrated by the larger ORG reduction at the second follow-up. The most advanced stage patient within the cohort (RP03) also demonstrated the largest reduction in ORGedge (65.1% and 76.7% respectively at 9 and 15-month follow up).
We then compared ORGedge to standard clinical metrics of outer retinal structure (Fig. 5). Comparison of the reduction in ORGedge against EZ width and OS length for the most recent follow-up visits is shown. Note that OS length in Fig. 5 is obtained from the same locations and regions-of-interest as the ORGedge, facilitating a direct comparison between cone structure and function at the edge of the healthy island. Significantly greater reduction in ORGedge amplitude was observed compared to OSL and EZ width for RP01, 02, 03 and 04 (p < 0.02, Wilcoxon signed-rank test). For RP05, the small but significant reduction in ORGedge was not accompanied by changes in EZ width.
Comparison between ORGedge, OS length, and EZ-width for the five RP patients. Statistical significance values obtained from the Wilcoxon signed-rank test are noted in the plot.
Deterioration in cone structure, measured by a reduction in OSL and EZ, was less pronounced; the change in OS length and EZ-width was 5.7% ± 1.2% and 4.5% ± 5.9% respectively. The comparative reductions in EZ width versus OS length were not statistically different except for in RP04. Overall, these findings demonstrate that ORG detection of cone dysfunction precedes the loss of cone structure and provides an early and otherwise sub-clinical biomarker of disease progression.
Discussion
This is the first study to assess longitudinal disease progression using ORG and highlights its vast potential as a sensitive biomarker to precisely monitor progression of outer retinal disease. While RP was chosen as an example of outer retinal degeneration to assess the sensitivity of ORG to detect progression, the findings could be applicable across a broad range of primary and secondary photoreceptor diseases, including geographic atrophy in age-related macular degeneration (AMD) and other inherited retinal diseases, where the structure and function of the outer retinal complex is compromised 13,59,60. The evolution of ORG used in this study, dubbed CoORG or Coarse-scale ORG, does not require an adaptive optics module and sacrifices cellular resolution for increased field-of-view and high-throughput, patient-friendly imaging 56. Furthermore, patients with characteristics such as cataracts and excessive eye movements that would preclude adaptive optics imaging are accessible within the CoORG paradigm. Longitudinal study of the same patients and retinal locations over time as demonstrated here offers inherent control over inter- and intra-subject dependent factors that cause variability in the ORG, facilitating effective comparisons. In the future, documenting the normative characteristics of the ORG versus eccentricity 56 and age are important considerations for its wide-spread application.
Disease progression measured in ORG was compared to standard clinical assays. EZ width in OCT is one of the key biomarkers that reflects the remnant inner-segment-EZ structure of the photoreceptors. Here, we observed a 5% annual decline in EZ width in our cohort, a finding that closely aligns with the 5-7% reduction rate reported in previous studies 6,11. While EZ width is a highly repeatable marker of advanced-stage outer retinal degeneration 7,55, it does not convey functional information of the outer retina, nor the viability of the photoreceptor outer segment. The constriction of hyper-AF rings observed in FAF provides a biomarker for progression and is shown to have low test-retest variability 55. In RP, the annual horizontal and vertical rates of decline in hyper-AF ring size were reported to be 4.1% and 4.0%, respectively 55. In our study, we observed similar rates of annual decline over a 5-year period for RP01, with horizontal and vertical reductions of 4.1% and 3.4%, respectively.
As an add-on to OCT imaging, the ORG seamlessly integrates the assessment of structure and function in the same platform with high sensitivity and spatial localization, enabling the detection of functional changes that are anchored to clinically relevant structural disease phenotypes such as EZ width and OS length. This is of critical importance not only to compare against standard clinical measures of retinal structure but also to obtain granular insight into the spatially heterogeneous pattern of disease progression, such as in sectoral RP or geographic atrophy. As expected from the typical pattern of progression in RP, from the periphery to the fovea, the highly variable border region near the healthy island denoted by ORGedge showed the largest reduction over time. In contrast, cone function in the central healthy area, denoted by ORGcent, showed minimal change over time. (Figure 4B-C). However, cone function in the central retina appeared to be compromised compared to controls even at the first time point, as shown in Table 2, consistent with cross-sectional reports of ORG in RP 21,39. The ORGtot shows intermediate reduction in cone function compared to ORGedge and ORGcent (Figure 4B). Overall, targeted regional analysis as introduced here for ORG, based on previous suggestions for visual sensitivity 57,58, enables capturing the spatially localized and heterogenous pattern of disease progression as well as its comparison against more global clinical metrics.
As shown in Fig 5, the reduction in cone function with ORG over time exceeds that observed in EZ width and OS length. EZ width and OSL decreased by 4.5% ± 5.9% and 6.5% ± 1.4%, respectively (Fig. 5), approximately 9.9 and 6.9 times less than the reduction noted in ORGedge. The ORGedge revealed an average reduction of 44.7% ± 5.3% including the very early-stage subject (RP05). If RP05 were excluded, the mean ORG reduction in the remaining patients would increase to 54.8% ± 3.1%. The comparison against ORGtot was more modest, where reduction in overall cone function with ORG exceeds reductions in EZ width and OS length by 2.7x and 1.9x respectively (12.3% for ORG vs. 4.5% for EZ width and 6.5% for OS length). Whereas the EZ width can be treated as global metric of outer retinal health encompassing both the central healthy island and the transition zone, the breakdown of OS length into edge, center and total allows a more regional comparison between structure and function. Comparing Figure 4B versus Figure 4C, it is evident that reduction in cone function over time generally exceeds the reduction in OS length, whether assessed at the edge of the healthy island, or as a whole.
The growing landscape of clinical trials, including the advancements in novel gene-augmentation and gene-agnostic therapies for outer retinal diseases, underscores the need for outcome measures that are safe, sensitive, and efficient. These measures are particularly critical at early time points, when interventions may be most effective, or when the therapeutic effects can be assessed earlier during a clinical trial. The approval of voretigene neparvovec (Luxturna) for patients with RPE65 mutations causing Leber Congenital Amaurosis (LCA) represented a major advance in human vision restoration using gene therapy. In addition, gene-editing for CEP290-associated retinal degeneration has shown promising early results in clinical trials. In the context of geographic atrophy in AMD, pegcetacoplan and avacincaptad pegol drugs have recently received FDA approval for slowing disease progression by targeting the complement pathway 61–63. EZ-width and FAF are commonly used as clinical trial outcome measures. Efforts aimed at slowing or reversing disease progression would benefit from a faster and more sensitive biomarker that could ultimately lead to a shorter pathway for therapeutic testing and approval. This study marks a significant step in this direction. The low test-retest variability (∼4%) coupled with the high sensitivity in detecting annual rates of reduction in cone function highlights the potential of ORG to augment longitudinal studies of retinal disease and response to therapeutic interventions. Accordingly, for a treatment to show measurable effect with ORG, it would need to exhibit a minimum of 4% preservation or restoration of cone function, while a treatment effect would be measurable in a significantly shorter timespan compared to the current outcome measures.
Limitations
The study sample size is small, which may constrain statistical power and generalizability, specifically with respect to drawing genotype-phenotype correlations. In addition, the longitudinal study duration is limited to 21 months. Nevertheless, the ORG measurements showed a high test-retest reliability over repeat measurements, and significant disease progression was observed with ORG, even within the relatively short timeframe and in those with limited progression with standard clinical imaging. Another limitation of our study is the lack of longitudinal microperimetry in the same subjects. The addition of this important biomarker would enable relating the change in visual field to the degradation noted here in ORG and retinal structure. Previous work shows that retinal areas with sub-normal cone function measured with ORG 21 may exhibit normal visual sensitivity in RP, while IRD patients with loss of up to ∼62% of cones still exhibit normal visual acuity and sensitivity 15. This suggests that subjective tests of visual function may be less sensitive compared to objective tests of cone function such as ORG in tracking progression.
Conclusions
Overall, this study highlights the ability of ORG to capture early changes in photoreceptor function over time that are otherwise undetectable in standard clinical imaging and often precede structural deterioration. By enabling the detection of functional impairments before structural changes become apparent, ORG is poised to play a pivotal role in clinical practice and therapeutic trials. As treatments continue to evolve, the incorporation of ORG into clinical trials will accelerate the timeline and improve sensitivity for monitoring treatment efficacy, ultimately shortening the assessment period and enhancing patient outcomes.
Acknowledgements/Disclosure
The following sources of funding are acknowledged: NIH grant U01EY032055, EY029710, Unrestricted grant from the Research to Prevent Blindness, Dawn’s Light Foundation, George and Martina Kren Professorship in Vision Research. Vimal Pandiyan and Ramkumar Sabesan have filed a patent on the line-scan OCT technology used here for optoretinography (PCT/US2020/029984).
Footnotes
The website author affiliations updated. Just to make sure the doi's author affiliations is consistent with the manuscript we submitted previously.
References
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos